The neurotrophic hypothesis of depression states that the major depressive episode is associated with lower neurotrophic factors levels, which increase with amelioration of depressive symptoms. However, this hypothesis has not been extended to investigate neurotrophic factors other than the brain-derived neurotrophic factor (BDNF). We therefore explored whether plasma levels of neurotrophins 3 (NT-3) and 4 (NT-4), nerve growth factor (NGF) and glial cell line derived neurotrophic factor (GDNF) changed after antidepressant treatment and correlated with treatment response. Seventy-three patients with moderate-to-severe, antidepressant-free unipolar depression were assigned to a pharmacological (sertraline) and a non-pharmacological (transcranial direct current stimulation, tDCS) intervention in a randomized, 2 × 2, placebo-controlled design. The plasma levels of NT-3, NT-4, NGF and GDNF were determined by enzyme-linked immunosorbent assay before and after a 6-week treatment course and analyzed according to clinical response and allocation group. We found that tDCS and sertraline (separately and combined) produced significant improvement in depressive symptoms. Plasma levels of all neurotrophic factors were similar across groups at baseline and remained significantly unchanged regardless of the intervention and of clinical response. Also, baseline plasma levels were not associated with clinical response. To conclude, in this 6-week placebo-controlled trial, NT-3, NT-4, NGF and GDNF plasma levels did not significantly change with sertraline or tDCS. These data suggest that these neurotrophic factors are not surrogate biomarkers of treatment response or involved in the antidepressant mechanisms of tDCS.
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Introduction
The neurotrophic hypothesis of depression postulates that the depressive state is associated with decreased neuroplasticity, neuronal atrophy and/or aberrant neurogenesis in key brain areas related to mood and memory (Lang and Borgwardt, 2013) . In this context, successful antidepressant treatment response is associated with an increase in the expression of neurotrophic factors related to neuronal growth, survival (Duman and Monteggia, 2006) and neuroplasticity (Brunoni et al., 2008; Sen et al., 2008) . These neurotrophic factors include the neurotrophin family (such as NGF and BDNF) and other CNS factors such as the GDNF (Jiang and Salton, 2013; Neto et al., 2011) . Particularly, BDNF has been extensively investigated, with several studies showing that its blood levels are lower in depressed patients compared to healthy controls, and that its blood levels increase Abbreviations: NT-3, neurotrophin-3; NT-4, neurotrophin-4; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; CNS, central nervous system; GDNF, glial cell derived neurotrophic factor; TrK, tyrosine kinase; tDCS, transcranial direct current stimulation; DLPFC, dorsolateral prefrontal cortex; SELECT-TDCS, Sertraline vs. Electric Current Therapy for Treating Depression Clinical Study; MINI, Mini International Neuropsychiatric Interview; HDRS, Hamilton Depression Rating Score; MADRS, Montgomery-Asberg Depression Rating Scale; ELISA, enzyme-linked immunosorbent assay; ANOVA, analysis of variance; SD, standard deviation; ANCOVA, analysis of covariance; SSRI, selective serotonin reuptake inhibitor.
